Northern Trust’s Aquestive Therapeutics AQST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.46M | Buy |
831,151
+98,647
| +13% | +$415K | ﹤0.01% | 2837 |
|
|
2026
Q1 | $3.04M | Sell |
732,504
-10,290
| -1% | -$41.8K | ﹤0.01% | 2736 |
|
|
2025
Q4 | $4.8M | Buy |
742,794
+59,926
| +9% | +$373K | ﹤0.01% | 2499 |
|
|
2025
Q3 | $3.82M | Buy |
682,868
+38,949
| +6% | +$168K | ﹤0.01% | 2666 |
|
|
2025
Q2 | $2.13M | Buy |
643,919
+56,091
| +10% | +$161K | ﹤0.01% | 2942 |
|
|
2025
Q1 | $1.7M | Sell |
587,828
-11,984
| -2% | -$36.3K | ﹤0.01% | 3002 |
|
|
2024
Q4 | $2.14M | Buy |
599,812
+18,199
| +3% | +$83.9K | ﹤0.01% | 2990 |
|
|
2024
Q3 | $2.9M | Buy |
581,613
+387,589
| +200% | +$1.51M | ﹤0.01% | 2772 |
|
|
2024
Q2 | $504K | Buy |
194,024
+96,104
| +98% | +$321K | ﹤0.01% | 3507 |
|
|
2024
Q1 | $417K | Buy |
97,920
+6,728
| +7% | +$22.4K | ﹤0.01% | 3622 |
|
|
2023
Q4 | $184K | Buy |
91,192
+25,692
| +39% | +$45.4K | ﹤0.01% | 3927 |
|
|
2023
Q3 | $100K | Hold |
65,500
| – | – | ﹤0.01% | 4014 |
|
|
2023
Q2 | $108K | Buy |
65,500
+5,672
| +9% | +$10.3K | ﹤0.01% | 4017 |
|
|
2023
Q1 | $68.2K | Sell |
59,828
-2,262
| -4% | -$1.96K | ﹤0.01% | 4183 |
|
|
2022
Q4 | $56K | Hold |
62,090
| – | – | ﹤0.01% | 4258 |
|
|
2022
Q3 | $73K | Buy |
62,090
+14,541
| +31% | +$16.4K | ﹤0.01% | 4213 |
|
|
2022
Q2 | $30K | Sell |
47,549
-10
| -0% | -$13 | ﹤0.01% | 4553 |
|
|
2022
Q1 | $124K | Buy |
47,559
+10
| +0% | +$29 | ﹤0.01% | 4284 |
|
|
2021
Q4 | $185K | Buy |
47,549
+1,820
| +4% | +$9.13K | ﹤0.01% | 4221 |
|
|
2021
Q3 | $199K | Buy |
45,729
+275
| +0.6% | +$1.08K | ﹤0.01% | 4181 |
|
|
2021
Q2 | $181K | Sell |
45,454
-166,948
| -79% | -$667K | ﹤0.01% | 4195 |
|
|
2021
Q1 | $1.1M | Sell |
212,402
-13,202
| -6% | -$70.2K | ﹤0.01% | 3547 |
|
|
2020
Q4 | $1.21M | Sell |
225,604
-6,299
| -3% | -$37.8K | ﹤0.01% | 3440 |
|
|
2020
Q3 | $1.13M | Sell |
231,903
-5,852
| -2% | -$38.3K | ﹤0.01% | 3347 |
|
|
2020
Q2 | $1.16M | Buy |
237,755
+190,451
| +403% | +$877K | ﹤0.01% | 3305 |
|
|
2020
Q1 | $104K | Buy |
47,304
+33,327
| +238% | +$127K | ﹤0.01% | 3807 |
|
|
2019
Q4 | $81K | Sell |
13,977
-826
| -6% | -$4.3K | ﹤0.01% | 3969 |
|
|
2019
Q3 | $47K | Sell |
14,803
-83,839
| -85% | -$314K | ﹤0.01% | 4056 |
|
|
2019
Q2 | $414K | Sell |
98,642
-7,628
| -7% | -$39.1K | ﹤0.01% | 3607 |
|
|
2019
Q1 | $734K | Buy |
106,270
+48,201
| +83% | +$338K | ﹤0.01% | 3446 |
|
|
2018
Q4 | $366K | Buy |
58,069
+317
| +0.5% | +$4K | ﹤0.01% | 3625 |
|
|
2018
Q3 | $1.01M | Buy |
+57,752
| New | +$952K | ﹤0.01% | 3465 |
|
Other funds holding AQST
BCM
RI
SB
SCM
Northern Trust's AQST Position: Q2 2026 in Review
Northern Trust increased its Aquestive Therapeutics (AQST) stake by 13% in Q2 2026, buying an estimated $415K and bringing the position to 831,151 shares worth $3.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2837.
Northern Trust first reported a position in AQST in Q3 2018 and has held it in 32 quarters since. The position peaked at $4.8M in Q4 2025. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.
- Northern Trust held 831,151 shares of Aquestive Therapeutics worth $3.46M as of Q2 2026.
- Northern Trust bought 98,647 Aquestive Therapeutics shares in Q2 2026, an estimated $415K.
- Aquestive Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #2837 holding.
- Northern Trust first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 32 quarters since.
- Northern Trust's Aquestive Therapeutics position peaked at $4.8M in Q4 2025.
- 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.
Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.